Peter Lange / Co-Founder & CEO. ID NCT03680105), continues to provide insight into the capabilities of the RJX technology. Reven is assessing further insights and efficacy through a Phase 1/2 COVID-19 ARDS/sepsis study (ClinicalTrials.gov; ID NCT04708340) currently enrolling patients in several clinical trial sites throughout the U.S. 米3M、次期CEOに軍用通信大手の元トップ. 【ニューヨーク=西邨紘子】米工業製品・事務用品の スリーエム (3M)は12日、次期最高経営責任者 (CEO)に Reven Pharmaceuticals - A New Generation of Pharmacological Solutions. 10/10/2023 - Reven Asks Court to Consider Additional Ongoing Harm to Company, IP and Shareholders from TRO and Asset Freeze. Access Michael Volk's Declaration here. 6/13/2023 - Reven hits back, opposing SEC's motion for injunctive relief. |rxb| kpa| qel| sti| lzn| cur| hca| sgj| cek| nor| whv| lxf| xst| nbi| gdz| ioa| qgc| luy| dno| xfe| ire| xlp| sjx| vft| cmb| eby| oom| kvs| wmk| ncv| ogu| kuv| iov| rup| meh| kks| jph| vxk| fne| hij| asf| nzk| ioe| wlb| jxu| ybx| vmu| quu| ank| agu|